nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.494	1	CiPCiCtD
Vandetanib—KDR—melanoma	0.0688	0.358	CbGaD
Vandetanib—VEGFA—melanoma	0.0583	0.304	CbGaD
Vandetanib—EGFR—melanoma	0.0492	0.256	CbGaD
Vandetanib—EGFR—Docetaxel—melanoma	0.0321	0.206	CbGbCtD
Vandetanib—ORM1—Vemurafenib—melanoma	0.0253	0.162	CbGbCtD
Vandetanib—ABCC1—Vemurafenib—melanoma	0.0231	0.148	CbGbCtD
Vandetanib—ALB—melanoma	0.0157	0.0817	CbGaD
Vandetanib—ABCG2—Vemurafenib—melanoma	0.0155	0.099	CbGbCtD
Vandetanib—ABCC1—Dactinomycin—melanoma	0.0154	0.0983	CbGbCtD
Vandetanib—ALB—Vemurafenib—melanoma	0.0107	0.0682	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—melanoma	0.0103	0.0658	CbGbCtD
Vandetanib—ABCC1—Docetaxel—melanoma	0.00793	0.0508	CbGbCtD
Vandetanib—CYP3A4—Temozolomide—melanoma	0.0061	0.039	CbGbCtD
Vandetanib—ABCG2—Docetaxel—melanoma	0.00531	0.034	CbGbCtD
Vandetanib—CYP3A4—Vemurafenib—melanoma	0.00334	0.0214	CbGbCtD
Vandetanib—PTK6—skin epidermis—melanoma	0.0013	0.0415	CbGeAlD
Vandetanib—CYP3A4—Docetaxel—melanoma	0.00115	0.00734	CbGbCtD
Vandetanib—PTK6—hair follicle—melanoma	0.000931	0.0296	CbGeAlD
Vandetanib—KDR—umbilical vein—melanoma	0.000784	0.0249	CbGeAlD
Vandetanib—KDR—hindlimb—melanoma	0.000718	0.0228	CbGeAlD
Vandetanib—KDR—appendage—melanoma	0.000616	0.0196	CbGeAlD
Vandetanib—FLT4—endothelium—melanoma	0.000565	0.018	CbGeAlD
Vandetanib—RIPK2—endothelium—melanoma	0.000562	0.0179	CbGeAlD
Vandetanib—ERBB3—hair follicle—melanoma	0.000529	0.0168	CbGeAlD
Vandetanib—FLT4—blood vessel—melanoma	0.000521	0.0166	CbGeAlD
Vandetanib—RIPK2—blood vessel—melanoma	0.000519	0.0165	CbGeAlD
Vandetanib—MKNK1—hair follicle—melanoma	0.000497	0.0158	CbGeAlD
Vandetanib—EPHA8—eye—melanoma	0.000464	0.0148	CbGeAlD
Vandetanib—TEK—endothelium—melanoma	0.000455	0.0145	CbGeAlD
Vandetanib—MAP4K5—hair follicle—melanoma	0.000447	0.0142	CbGeAlD
Vandetanib—TEK—blood vessel—melanoma	0.000419	0.0133	CbGeAlD
Vandetanib—YES1—hair follicle—melanoma	0.000413	0.0131	CbGeAlD
Vandetanib—PTK6—skin of body—melanoma	0.000404	0.0128	CbGeAlD
Vandetanib—SRC—endothelium—melanoma	0.000404	0.0128	CbGeAlD
Vandetanib—SRC—blood vessel—melanoma	0.000373	0.0118	CbGeAlD
Vandetanib—KDR—endothelium—melanoma	0.000372	0.0118	CbGeAlD
Vandetanib—PTK6—mammalian vulva—melanoma	0.000369	0.0117	CbGeAlD
Vandetanib—EPHA5—eye—melanoma	0.000359	0.0114	CbGeAlD
Vandetanib—EPHA5—retina—melanoma	0.000356	0.0113	CbGeAlD
Vandetanib—Afatinib—ERBB4—melanoma	0.000352	0.118	CrCbGaD
Vandetanib—Bosutinib—PKMYT1—melanoma	0.000343	0.115	CrCbGaD
Vandetanib—KDR—blood vessel—melanoma	0.000343	0.0109	CbGeAlD
Vandetanib—RET—neck—melanoma	0.000329	0.0105	CbGeAlD
Vandetanib—TYRO3—skin of body—melanoma	0.000313	0.00994	CbGeAlD
Vandetanib—PDGFRB—blood vessel—melanoma	0.000297	0.00943	CbGeAlD
Vandetanib—Bosutinib—SYK—melanoma	0.000292	0.0978	CrCbGaD
Vandetanib—FLT4—eye—melanoma	0.000277	0.00882	CbGeAlD
Vandetanib—RIPK2—eye—melanoma	0.000276	0.00877	CbGeAlD
Vandetanib—LTK—head—melanoma	0.000275	0.00874	CbGeAlD
Vandetanib—RIPK2—retina—melanoma	0.000273	0.0087	CbGeAlD
Vandetanib—EPHA8—head—melanoma	0.000264	0.00838	CbGeAlD
Vandetanib—STK35—skin of body—melanoma	0.00026	0.00828	CbGeAlD
Vandetanib—Afatinib—ERBB2—melanoma	0.00026	0.0872	CrCbGaD
Vandetanib—MKNK1—eye—melanoma	0.000248	0.00789	CbGeAlD
Vandetanib—MKNK1—retina—melanoma	0.000246	0.00782	CbGeAlD
Vandetanib—KDR—neck—melanoma	0.000245	0.0078	CbGeAlD
Vandetanib—AXL—eye—melanoma	0.000244	0.00776	CbGeAlD
Vandetanib—AXL—retina—melanoma	0.000242	0.00769	CbGeAlD
Vandetanib—RIPK2—skin of body—melanoma	0.00024	0.00763	CbGeAlD
Vandetanib—Bosutinib—CDK2—melanoma	0.000238	0.0797	CrCbGaD
Vandetanib—Bosutinib—EPHA2—melanoma	0.000238	0.0797	CrCbGaD
Vandetanib—FMO3—eye—melanoma	0.000237	0.00752	CbGeAlD
Vandetanib—ERBB3—skin of body—melanoma	0.00023	0.00731	CbGeAlD
Vandetanib—EGFR—mammalian vulva—melanoma	0.000226	0.00718	CbGeAlD
Vandetanib—Bosutinib—MAP2K2—melanoma	0.000221	0.0741	CrCbGaD
Vandetanib—EPHA6—head—melanoma	0.00022	0.00699	CbGeAlD
Vandetanib—VEGFA—mammalian vulva—melanoma	0.000218	0.00694	CbGeAlD
Vandetanib—FMO1—mammalian vulva—melanoma	0.000217	0.00691	CbGeAlD
Vandetanib—ABCC1—hair follicle—melanoma	0.000215	0.00683	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—melanoma	0.000214	0.0068	CbGeAlD
Vandetanib—AXL—skin of body—melanoma	0.000212	0.00675	CbGeAlD
Vandetanib—PDGFRB—neck—melanoma	0.000212	0.00675	CbGeAlD
Vandetanib—YES1—eye—melanoma	0.000206	0.00655	CbGeAlD
Vandetanib—YES1—retina—melanoma	0.000204	0.00649	CbGeAlD
Vandetanib—EPHA5—head—melanoma	0.000204	0.00649	CbGeAlD
Vandetanib—TYRO3—head—melanoma	0.000204	0.00649	CbGeAlD
Vandetanib—LYN—head—melanoma	0.000203	0.00645	CbGeAlD
Vandetanib—BMPR1B—head—melanoma	0.0002	0.00635	CbGeAlD
Vandetanib—MAP3K19—head—melanoma	0.0002	0.00635	CbGeAlD
Vandetanib—FYN—skin of body—melanoma	0.000199	0.00632	CbGeAlD
Vandetanib—SRC—eye—melanoma	0.000198	0.0063	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—melanoma	0.000197	0.00626	CbGeAlD
Vandetanib—SRC—retina—melanoma	0.000196	0.00625	CbGeAlD
Vandetanib—BLK—lymph node—melanoma	0.000195	0.00619	CbGeAlD
Vandetanib—FGR—mammalian vulva—melanoma	0.000194	0.00618	CbGeAlD
Vandetanib—LCK—mammalian vulva—melanoma	0.000194	0.00618	CbGeAlD
Vandetanib—AXL—mammalian vulva—melanoma	0.000194	0.00616	CbGeAlD
Vandetanib—LTK—lymph node—melanoma	0.000193	0.00612	CbGeAlD
Vandetanib—FMO3—mammalian vulva—melanoma	0.000188	0.00597	CbGeAlD
Vandetanib—SLK—mammalian vulva—melanoma	0.000186	0.00593	CbGeAlD
Vandetanib—EPHB6—skin of body—melanoma	0.000186	0.0059	CbGeAlD
Vandetanib—KDR—eye—melanoma	0.000182	0.0058	CbGeAlD
Vandetanib—FYN—mammalian vulva—melanoma	0.000181	0.00576	CbGeAlD
Vandetanib—KDR—retina—melanoma	0.000181	0.00575	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—melanoma	0.000177	0.00563	CbGeAlD
Vandetanib—SRC—skin of body—melanoma	0.000172	0.00548	CbGeAlD
Vandetanib—STK35—head—melanoma	0.00017	0.0054	CbGeAlD
Vandetanib—EPHB6—mammalian vulva—melanoma	0.000169	0.00538	CbGeAlD
Vandetanib—Bosutinib—MAP2K1—melanoma	0.000168	0.0562	CrCbGaD
Vandetanib—Bosutinib—PTK2B—melanoma	0.000168	0.0562	CrCbGaD
Vandetanib—YES1—mammalian vulva—melanoma	0.000164	0.0052	CbGeAlD
Vandetanib—STK10—mammalian vulva—melanoma	0.000162	0.00515	CbGeAlD
Vandetanib—PDGFRB—eye—melanoma	0.000158	0.00502	CbGeAlD
Vandetanib—FLT4—head—melanoma	0.000158	0.00501	CbGeAlD
Vandetanib—RIPK2—head—melanoma	0.000157	0.00498	CbGeAlD
Vandetanib—FMO1—head—melanoma	0.000155	0.00494	CbGeAlD
Vandetanib—Bosutinib—ERBB4—melanoma	0.000153	0.0514	CrCbGaD
Vandetanib—IRAK4—head—melanoma	0.000153	0.00486	CbGeAlD
Vandetanib—PLK4—lymph node—melanoma	0.000152	0.00483	CbGeAlD
Vandetanib—ERBB3—head—melanoma	0.00015	0.00477	CbGeAlD
Vandetanib—KDR—mammalian vulva—melanoma	0.000145	0.0046	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—melanoma	0.000145	0.0046	CbGeAlD
Vandetanib—MKNK1—head—melanoma	0.000141	0.00448	CbGeAlD
Vandetanib—ABL1—eye—melanoma	0.000141	0.00447	CbGeAlD
Vandetanib—BMPR1B—lymph node—melanoma	0.00014	0.00445	CbGeAlD
Vandetanib—ABL1—retina—melanoma	0.000139	0.00443	CbGeAlD
Vandetanib—FGR—head—melanoma	0.000139	0.00442	CbGeAlD
Vandetanib—RET—head—melanoma	0.000139	0.00442	CbGeAlD
Vandetanib—AXL—head—melanoma	0.000139	0.0044	CbGeAlD
Vandetanib—PDGFRB—skin of body—melanoma	0.000137	0.00437	CbGeAlD
Vandetanib—FMO3—head—melanoma	0.000134	0.00427	CbGeAlD
Vandetanib—FYN—head—melanoma	0.00013	0.00412	CbGeAlD
Vandetanib—MAP4K5—head—melanoma	0.000127	0.00403	CbGeAlD
Vandetanib—TEK—head—melanoma	0.000127	0.00403	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—melanoma	0.000125	0.00398	CbGeAlD
Vandetanib—Afatinib—EGFR—melanoma	0.000123	0.0412	CrCbGaD
Vandetanib—ABL1—skin of body—melanoma	0.000122	0.00389	CbGeAlD
Vandetanib—FLT3—lymph node—melanoma	0.000121	0.00386	CbGeAlD
Vandetanib—EPHB6—head—melanoma	0.000121	0.00385	CbGeAlD
Vandetanib—STK35—lymph node—melanoma	0.000119	0.00378	CbGeAlD
Vandetanib—YES1—head—melanoma	0.000117	0.00372	CbGeAlD
Vandetanib—ABL2—lymph node—melanoma	0.000116	0.00369	CbGeAlD
Vandetanib—STK10—head—melanoma	0.000116	0.00369	CbGeAlD
Vandetanib—Dry skin—Temozolomide—melanoma	0.000114	0.00317	CcSEcCtD
Vandetanib—EGFR—lymph node—melanoma	0.000113	0.0036	CbGeAlD
Vandetanib—Hypokalaemia—Temozolomide—melanoma	0.000113	0.00315	CcSEcCtD
Vandetanib—SRC—head—melanoma	0.000113	0.00358	CbGeAlD
Vandetanib—ABL1—mammalian vulva—melanoma	0.000112	0.00355	CbGeAlD
Vandetanib—Dysphagia—Carmustine—melanoma	0.000111	0.00309	CcSEcCtD
Vandetanib—Neutropenia—Dactinomycin—melanoma	0.000111	0.00309	CcSEcCtD
Vandetanib—Stomatitis—Bleomycin—melanoma	0.000111	0.00308	CcSEcCtD
Vandetanib—FLT4—lymph node—melanoma	0.00011	0.00351	CbGeAlD
Vandetanib—RIPK2—lymph node—melanoma	0.00011	0.00349	CbGeAlD
Vandetanib—Alanine aminotransferase increased—Temozolomide—melanoma	0.00011	0.00305	CcSEcCtD
Vandetanib—VEGFA—lymph node—melanoma	0.000109	0.00348	CbGeAlD
Vandetanib—Colitis—Docetaxel—melanoma	0.000109	0.00304	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000109	0.00303	CcSEcCtD
Vandetanib—FMO1—lymph node—melanoma	0.000109	0.00346	CbGeAlD
Vandetanib—Haematuria—Bleomycin—melanoma	0.000108	0.00301	CcSEcCtD
Vandetanib—Dysphagia—Temozolomide—melanoma	0.000107	0.00299	CcSEcCtD
Vandetanib—IRAK4—lymph node—melanoma	0.000107	0.00341	CbGeAlD
Vandetanib—Pneumonia—Dactinomycin—melanoma	0.000106	0.00297	CcSEcCtD
Vandetanib—ERBB3—lymph node—melanoma	0.000105	0.00334	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000105	0.00292	CcSEcCtD
Vandetanib—Neutropenia—Carmustine—melanoma	0.000104	0.00289	CcSEcCtD
Vandetanib—Decreased appetite—Vemurafenib—melanoma	0.000104	0.00289	CcSEcCtD
Vandetanib—KDR—head—melanoma	0.000104	0.00329	CbGeAlD
Vandetanib—MAP2K5—head—melanoma	0.000104	0.00329	CbGeAlD
Vandetanib—Bronchitis—Temozolomide—melanoma	0.000103	0.00288	CcSEcCtD
Vandetanib—Stomatitis—Dactinomycin—melanoma	0.000103	0.00287	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000103	0.00287	CcSEcCtD
Vandetanib—Fatigue—Vemurafenib—melanoma	0.000103	0.00287	CcSEcCtD
Vandetanib—Neoplasm—Docetaxel—melanoma	0.000103	0.00287	CcSEcCtD
Vandetanib—Haemoglobin—Bleomycin—melanoma	0.000102	0.00285	CcSEcCtD
Vandetanib—Constipation—Vemurafenib—melanoma	0.000102	0.00285	CcSEcCtD
Vandetanib—Haemorrhage—Bleomycin—melanoma	0.000102	0.00284	CcSEcCtD
Vandetanib—Dysuria—Temozolomide—melanoma	0.0001	0.0028	CcSEcCtD
Vandetanib—Neutropenia—Temozolomide—melanoma	0.0001	0.0028	CcSEcCtD
Vandetanib—Hyperglycaemia—Carmustine—melanoma	0.0001	0.00279	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Temozolomide—melanoma	9.98e-05	0.00278	CcSEcCtD
Vandetanib—Pneumonia—Carmustine—melanoma	9.97e-05	0.00278	CcSEcCtD
Vandetanib—Pollakiuria—Temozolomide—melanoma	9.92e-05	0.00276	CcSEcCtD
Vandetanib—Depression—Carmustine—melanoma	9.88e-05	0.00275	CcSEcCtD
Vandetanib—Sepsis—Docetaxel—melanoma	9.88e-05	0.00275	CcSEcCtD
Vandetanib—MKNK1—lymph node—melanoma	9.86e-05	0.00313	CbGeAlD
Vandetanib—Photosensitivity reaction—Temozolomide—melanoma	9.8e-05	0.00273	CcSEcCtD
Vandetanib—Renal failure—Carmustine—melanoma	9.74e-05	0.00271	CcSEcCtD
Vandetanib—FGR—lymph node—melanoma	9.74e-05	0.0031	CbGeAlD
Vandetanib—RET—lymph node—melanoma	9.74e-05	0.0031	CbGeAlD
Vandetanib—LCK—lymph node—melanoma	9.74e-05	0.0031	CbGeAlD
Vandetanib—Weight decreased—Temozolomide—melanoma	9.72e-05	0.00271	CcSEcCtD
Vandetanib—AXL—lymph node—melanoma	9.7e-05	0.00308	CbGeAlD
Vandetanib—Hyperglycaemia—Temozolomide—melanoma	9.69e-05	0.0027	CcSEcCtD
Vandetanib—Stomatitis—Carmustine—melanoma	9.66e-05	0.00269	CcSEcCtD
Vandetanib—Urinary tract infection—Carmustine—melanoma	9.63e-05	0.00268	CcSEcCtD
Vandetanib—Pneumonia—Temozolomide—melanoma	9.63e-05	0.00268	CcSEcCtD
Vandetanib—Infestation—Temozolomide—melanoma	9.58e-05	0.00267	CcSEcCtD
Vandetanib—Infestation NOS—Temozolomide—melanoma	9.58e-05	0.00267	CcSEcCtD
Vandetanib—Depression—Temozolomide—melanoma	9.55e-05	0.00266	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Temozolomide—melanoma	9.49e-05	0.00264	CcSEcCtD
Vandetanib—Body temperature increased—Vemurafenib—melanoma	9.45e-05	0.00263	CcSEcCtD
Vandetanib—FMO3—lymph node—melanoma	9.4e-05	0.00299	CbGeAlD
Vandetanib—SLK—lymph node—melanoma	9.34e-05	0.00297	CbGeAlD
Vandetanib—Stomatitis—Temozolomide—melanoma	9.33e-05	0.0026	CcSEcCtD
Vandetanib—Urinary tract infection—Temozolomide—melanoma	9.31e-05	0.00259	CcSEcCtD
Vandetanib—Erlotinib—CYP1B1—melanoma	9.21e-05	0.0309	CrCbGaD
Vandetanib—FYN—lymph node—melanoma	9.08e-05	0.00289	CbGeAlD
Vandetanib—Hepatobiliary disease—Temozolomide—melanoma	9.06e-05	0.00252	CcSEcCtD
Vandetanib—Alopecia—Bleomycin—melanoma	9.01e-05	0.00251	CcSEcCtD
Vandetanib—Erythema multiforme—Dactinomycin—melanoma	8.99e-05	0.0025	CcSEcCtD
Vandetanib—Sinusitis—Temozolomide—melanoma	8.98e-05	0.0025	CcSEcCtD
Vandetanib—PDGFRB—head—melanoma	8.96e-05	0.00285	CbGeAlD
Vandetanib—Haemoglobin—Carmustine—melanoma	8.94e-05	0.00249	CcSEcCtD
Vandetanib—Haemorrhage—Carmustine—melanoma	8.9e-05	0.00248	CcSEcCtD
Vandetanib—TEK—lymph node—melanoma	8.87e-05	0.00282	CbGeAlD
Vandetanib—MAP4K5—lymph node—melanoma	8.87e-05	0.00282	CbGeAlD
Vandetanib—Atrial fibrillation—Docetaxel—melanoma	8.72e-05	0.00243	CcSEcCtD
Vandetanib—Erlotinib—EGFR—melanoma	8.69e-05	0.0291	CrCbGaD
Vandetanib—Dermatitis bullous—Docetaxel—melanoma	8.65e-05	0.00241	CcSEcCtD
Vandetanib—Haemoglobin—Temozolomide—melanoma	8.64e-05	0.00241	CcSEcCtD
Vandetanib—Haemorrhage—Temozolomide—melanoma	8.6e-05	0.00239	CcSEcCtD
Vandetanib—Asthenia—Vemurafenib—melanoma	8.57e-05	0.00239	CcSEcCtD
Vandetanib—Visual impairment—Carmustine—melanoma	8.57e-05	0.00239	CcSEcCtD
Vandetanib—ABCC1—mammalian vulva—melanoma	8.5e-05	0.0027	CbGeAlD
Vandetanib—Urinary tract disorder—Temozolomide—melanoma	8.49e-05	0.00236	CcSEcCtD
Vandetanib—EPHB6—lymph node—melanoma	8.48e-05	0.0027	CbGeAlD
Vandetanib—Cardiac failure—Docetaxel—melanoma	8.47e-05	0.00236	CcSEcCtD
Vandetanib—Pruritus—Vemurafenib—melanoma	8.46e-05	0.00235	CcSEcCtD
Vandetanib—Lethargy—Docetaxel—melanoma	8.43e-05	0.00235	CcSEcCtD
Vandetanib—Urethral disorder—Temozolomide—melanoma	8.43e-05	0.00235	CcSEcCtD
Vandetanib—Alopecia—Dactinomycin—melanoma	8.4e-05	0.00234	CcSEcCtD
Vandetanib—Eye disorder—Carmustine—melanoma	8.31e-05	0.00232	CcSEcCtD
Vandetanib—Hyponatraemia—Docetaxel—melanoma	8.3e-05	0.00231	CcSEcCtD
Vandetanib—Visual impairment—Temozolomide—melanoma	8.28e-05	0.00231	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Docetaxel—melanoma	8.26e-05	0.0023	CcSEcCtD
Vandetanib—YES1—lymph node—melanoma	8.19e-05	0.0026	CbGeAlD
Vandetanib—Diarrhoea—Vemurafenib—melanoma	8.18e-05	0.00228	CcSEcCtD
Vandetanib—Erythema multiforme—Temozolomide—melanoma	8.13e-05	0.00226	CcSEcCtD
Vandetanib—STK10—lymph node—melanoma	8.12e-05	0.00258	CbGeAlD
Vandetanib—Eye disorder—Temozolomide—melanoma	8.03e-05	0.00224	CcSEcCtD
Vandetanib—ABL1—head—melanoma	7.99e-05	0.00254	CbGeAlD
Vandetanib—Cardiac disorder—Temozolomide—melanoma	7.98e-05	0.00222	CcSEcCtD
Vandetanib—Arrhythmia—Carmustine—melanoma	7.95e-05	0.00221	CcSEcCtD
Vandetanib—Dizziness—Vemurafenib—melanoma	7.9e-05	0.0022	CcSEcCtD
Vandetanib—SRC—lymph node—melanoma	7.88e-05	0.00251	CbGeAlD
Vandetanib—Alopecia—Carmustine—melanoma	7.86e-05	0.00219	CcSEcCtD
Vandetanib—Angiopathy—Temozolomide—melanoma	7.8e-05	0.00217	CcSEcCtD
Vandetanib—Mental disorder—Carmustine—melanoma	7.79e-05	0.00217	CcSEcCtD
Vandetanib—Mediastinal disorder—Temozolomide—melanoma	7.75e-05	0.00216	CcSEcCtD
Vandetanib—Malnutrition—Carmustine—melanoma	7.74e-05	0.00216	CcSEcCtD
Vandetanib—Cough—Bleomycin—melanoma	7.74e-05	0.00216	CcSEcCtD
Vandetanib—Dehydration—Docetaxel—melanoma	7.69e-05	0.00214	CcSEcCtD
Vandetanib—Vomiting—Vemurafenib—melanoma	7.6e-05	0.00212	CcSEcCtD
Vandetanib—Alopecia—Temozolomide—melanoma	7.6e-05	0.00212	CcSEcCtD
Vandetanib—Dry skin—Docetaxel—melanoma	7.57e-05	0.00211	CcSEcCtD
Vandetanib—Chest pain—Bleomycin—melanoma	7.55e-05	0.0021	CcSEcCtD
Vandetanib—Rash—Vemurafenib—melanoma	7.54e-05	0.0021	CcSEcCtD
Vandetanib—Mental disorder—Temozolomide—melanoma	7.53e-05	0.0021	CcSEcCtD
Vandetanib—Dermatitis—Vemurafenib—melanoma	7.53e-05	0.0021	CcSEcCtD
Vandetanib—Headache—Vemurafenib—melanoma	7.49e-05	0.00208	CcSEcCtD
Vandetanib—Malnutrition—Temozolomide—melanoma	7.48e-05	0.00208	CcSEcCtD
Vandetanib—Nasopharyngitis—Docetaxel—melanoma	7.39e-05	0.00206	CcSEcCtD
Vandetanib—Dysgeusia—Temozolomide—melanoma	7.33e-05	0.00204	CcSEcCtD
Vandetanib—Vision blurred—Carmustine—melanoma	7.3e-05	0.00203	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Docetaxel—melanoma	7.29e-05	0.00203	CcSEcCtD
Vandetanib—Tremor—Carmustine—melanoma	7.26e-05	0.00202	CcSEcCtD
Vandetanib—KDR—lymph node—melanoma	7.25e-05	0.00231	CbGeAlD
Vandetanib—MAP2K5—lymph node—melanoma	7.25e-05	0.00231	CbGeAlD
Vandetanib—Oedema—Bleomycin—melanoma	7.24e-05	0.00202	CcSEcCtD
Vandetanib—Infection—Bleomycin—melanoma	7.19e-05	0.002	CcSEcCtD
Vandetanib—Dysphagia—Docetaxel—melanoma	7.14e-05	0.00199	CcSEcCtD
Vandetanib—Nausea—Vemurafenib—melanoma	7.1e-05	0.00198	CcSEcCtD
Vandetanib—Thrombocytopenia—Bleomycin—melanoma	7.09e-05	0.00197	CcSEcCtD
Vandetanib—Vision blurred—Temozolomide—melanoma	7.05e-05	0.00196	CcSEcCtD
Vandetanib—ABCG2—mammalian vulva—melanoma	7.04e-05	0.00224	CbGeAlD
Vandetanib—Bronchospasm—Docetaxel—melanoma	7.03e-05	0.00196	CcSEcCtD
Vandetanib—Tremor—Temozolomide—melanoma	7.01e-05	0.00195	CcSEcCtD
Vandetanib—Oedema—Dactinomycin—melanoma	6.75e-05	0.00188	CcSEcCtD
Vandetanib—Convulsion—Carmustine—melanoma	6.71e-05	0.00187	CcSEcCtD
Vandetanib—Infection—Dactinomycin—melanoma	6.71e-05	0.00187	CcSEcCtD
Vandetanib—Hypertension—Carmustine—melanoma	6.69e-05	0.00186	CcSEcCtD
Vandetanib—Neutropenia—Docetaxel—melanoma	6.68e-05	0.00186	CcSEcCtD
Vandetanib—Thrombocytopenia—Dactinomycin—melanoma	6.61e-05	0.00184	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Bleomycin—melanoma	6.6e-05	0.00184	CcSEcCtD
Vandetanib—Chest pain—Carmustine—melanoma	6.59e-05	0.00184	CcSEcCtD
Vandetanib—Anxiety—Carmustine—melanoma	6.57e-05	0.00183	CcSEcCtD
Vandetanib—Cough—Temozolomide—melanoma	6.53e-05	0.00182	CcSEcCtD
Vandetanib—Paraesthesia—Bleomycin—melanoma	6.5e-05	0.00181	CcSEcCtD
Vandetanib—Convulsion—Temozolomide—melanoma	6.48e-05	0.00181	CcSEcCtD
Vandetanib—Weight decreased—Docetaxel—melanoma	6.46e-05	0.0018	CcSEcCtD
Vandetanib—Hypertension—Temozolomide—melanoma	6.46e-05	0.0018	CcSEcCtD
Vandetanib—Dyspnoea—Bleomycin—melanoma	6.46e-05	0.0018	CcSEcCtD
Vandetanib—Pneumonia—Docetaxel—melanoma	6.41e-05	0.00178	CcSEcCtD
Vandetanib—Arthralgia—Temozolomide—melanoma	6.37e-05	0.00177	CcSEcCtD
Vandetanib—Infestation NOS—Docetaxel—melanoma	6.37e-05	0.00177	CcSEcCtD
Vandetanib—Infestation—Docetaxel—melanoma	6.37e-05	0.00177	CcSEcCtD
Vandetanib—Anxiety—Temozolomide—melanoma	6.35e-05	0.00177	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	6.33e-05	0.00176	CcSEcCtD
Vandetanib—Oedema—Carmustine—melanoma	6.32e-05	0.00176	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Docetaxel—melanoma	6.31e-05	0.00176	CcSEcCtD
Vandetanib—Decreased appetite—Bleomycin—melanoma	6.29e-05	0.00175	CcSEcCtD
Vandetanib—Infection—Carmustine—melanoma	6.28e-05	0.00175	CcSEcCtD
Vandetanib—PDGFRB—lymph node—melanoma	6.27e-05	0.002	CbGeAlD
Vandetanib—Renal failure—Docetaxel—melanoma	6.26e-05	0.00174	CcSEcCtD
Vandetanib—Dry mouth—Temozolomide—melanoma	6.23e-05	0.00174	CcSEcCtD
Vandetanib—Stomatitis—Docetaxel—melanoma	6.21e-05	0.00173	CcSEcCtD
Vandetanib—Pain—Bleomycin—melanoma	6.19e-05	0.00172	CcSEcCtD
Vandetanib—Conjunctivitis—Docetaxel—melanoma	6.19e-05	0.00172	CcSEcCtD
Vandetanib—Thrombocytopenia—Carmustine—melanoma	6.19e-05	0.00172	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dactinomycin—melanoma	6.15e-05	0.00171	CcSEcCtD
Vandetanib—Oedema—Temozolomide—melanoma	6.11e-05	0.0017	CcSEcCtD
Vandetanib—Infection—Temozolomide—melanoma	6.07e-05	0.00169	CcSEcCtD
Vandetanib—Hepatobiliary disease—Docetaxel—melanoma	6.02e-05	0.00168	CcSEcCtD
Vandetanib—Epistaxis—Docetaxel—melanoma	6.01e-05	0.00167	CcSEcCtD
Vandetanib—Nervous system disorder—Temozolomide—melanoma	5.99e-05	0.00167	CcSEcCtD
Vandetanib—Thrombocytopenia—Temozolomide—melanoma	5.98e-05	0.00167	CcSEcCtD
Vandetanib—Skin disorder—Temozolomide—melanoma	5.93e-05	0.00165	CcSEcCtD
Vandetanib—ORM1—lymph node—melanoma	5.89e-05	0.00187	CbGeAlD
Vandetanib—Decreased appetite—Dactinomycin—melanoma	5.87e-05	0.00163	CcSEcCtD
Vandetanib—Fatigue—Dactinomycin—melanoma	5.82e-05	0.00162	CcSEcCtD
Vandetanib—Pain—Dactinomycin—melanoma	5.77e-05	0.00161	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Carmustine—melanoma	5.76e-05	0.0016	CcSEcCtD
Vandetanib—Haemoglobin—Docetaxel—melanoma	5.75e-05	0.0016	CcSEcCtD
Vandetanib—Body temperature increased—Bleomycin—melanoma	5.72e-05	0.00159	CcSEcCtD
Vandetanib—Haemorrhage—Docetaxel—melanoma	5.72e-05	0.00159	CcSEcCtD
Vandetanib—Insomnia—Carmustine—melanoma	5.72e-05	0.00159	CcSEcCtD
Vandetanib—Paraesthesia—Carmustine—melanoma	5.68e-05	0.00158	CcSEcCtD
Vandetanib—Urinary tract disorder—Docetaxel—melanoma	5.65e-05	0.00157	CcSEcCtD
Vandetanib—Dyspnoea—Carmustine—melanoma	5.63e-05	0.00157	CcSEcCtD
Vandetanib—Urethral disorder—Docetaxel—melanoma	5.6e-05	0.00156	CcSEcCtD
Vandetanib—ABL1—lymph node—melanoma	5.59e-05	0.00178	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Temozolomide—melanoma	5.56e-05	0.00155	CcSEcCtD
Vandetanib—Insomnia—Temozolomide—melanoma	5.52e-05	0.00154	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dactinomycin—melanoma	5.52e-05	0.00154	CcSEcCtD
Vandetanib—Visual impairment—Docetaxel—melanoma	5.51e-05	0.00153	CcSEcCtD
Vandetanib—Decreased appetite—Carmustine—melanoma	5.49e-05	0.00153	CcSEcCtD
Vandetanib—Paraesthesia—Temozolomide—melanoma	5.48e-05	0.00153	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Carmustine—melanoma	5.46e-05	0.00152	CcSEcCtD
Vandetanib—Dyspnoea—Temozolomide—melanoma	5.45e-05	0.00152	CcSEcCtD
Vandetanib—Gefitinib—EGFR—melanoma	5.44e-05	0.0182	CrCbGaD
Vandetanib—Erythema multiforme—Docetaxel—melanoma	5.41e-05	0.00151	CcSEcCtD
Vandetanib—Pain—Carmustine—melanoma	5.4e-05	0.00151	CcSEcCtD
Vandetanib—Constipation—Carmustine—melanoma	5.4e-05	0.00151	CcSEcCtD
Vandetanib—Dyspepsia—Temozolomide—melanoma	5.38e-05	0.0015	CcSEcCtD
Vandetanib—Bosutinib—EGFR—melanoma	5.35e-05	0.0179	CrCbGaD
Vandetanib—Eye disorder—Docetaxel—melanoma	5.34e-05	0.00149	CcSEcCtD
Vandetanib—Body temperature increased—Dactinomycin—melanoma	5.34e-05	0.00149	CcSEcCtD
Vandetanib—Abdominal pain—Dactinomycin—melanoma	5.34e-05	0.00149	CcSEcCtD
Vandetanib—Decreased appetite—Temozolomide—melanoma	5.31e-05	0.00148	CcSEcCtD
Vandetanib—Cardiac disorder—Docetaxel—melanoma	5.31e-05	0.00148	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Temozolomide—melanoma	5.27e-05	0.00147	CcSEcCtD
Vandetanib—Fatigue—Temozolomide—melanoma	5.27e-05	0.00147	CcSEcCtD
Vandetanib—Constipation—Temozolomide—melanoma	5.22e-05	0.00145	CcSEcCtD
Vandetanib—Pain—Temozolomide—melanoma	5.22e-05	0.00145	CcSEcCtD
Vandetanib—Asthenia—Bleomycin—melanoma	5.19e-05	0.00145	CcSEcCtD
Vandetanib—Angiopathy—Docetaxel—melanoma	5.19e-05	0.00144	CcSEcCtD
Vandetanib—Gastrointestinal pain—Carmustine—melanoma	5.17e-05	0.00144	CcSEcCtD
Vandetanib—ALB—lymph node—melanoma	5.16e-05	0.00164	CbGeAlD
Vandetanib—Mediastinal disorder—Docetaxel—melanoma	5.15e-05	0.00143	CcSEcCtD
Vandetanib—Pruritus—Bleomycin—melanoma	5.12e-05	0.00143	CcSEcCtD
Vandetanib—Arrhythmia—Docetaxel—melanoma	5.11e-05	0.00142	CcSEcCtD
Vandetanib—Alopecia—Docetaxel—melanoma	5.05e-05	0.00141	CcSEcCtD
Vandetanib—Mental disorder—Docetaxel—melanoma	5.01e-05	0.00139	CcSEcCtD
Vandetanib—Abdominal pain—Carmustine—melanoma	5e-05	0.00139	CcSEcCtD
Vandetanib—Body temperature increased—Carmustine—melanoma	5e-05	0.00139	CcSEcCtD
Vandetanib—Gastrointestinal pain—Temozolomide—melanoma	4.99e-05	0.00139	CcSEcCtD
Vandetanib—Malnutrition—Docetaxel—melanoma	4.98e-05	0.00139	CcSEcCtD
Vandetanib—Dysgeusia—Docetaxel—melanoma	4.87e-05	0.00136	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—melanoma	4.84e-05	0.00135	CcSEcCtD
Vandetanib—Body temperature increased—Temozolomide—melanoma	4.83e-05	0.00134	CcSEcCtD
Vandetanib—Abdominal pain—Temozolomide—melanoma	4.83e-05	0.00134	CcSEcCtD
Vandetanib—Muscle spasms—Docetaxel—melanoma	4.78e-05	0.00133	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—melanoma	4.62e-05	0.00129	CcSEcCtD
Vandetanib—Vomiting—Bleomycin—melanoma	4.6e-05	0.00128	CcSEcCtD
Vandetanib—Rash—Bleomycin—melanoma	4.57e-05	0.00127	CcSEcCtD
Vandetanib—Dermatitis—Bleomycin—melanoma	4.56e-05	0.00127	CcSEcCtD
Vandetanib—Asthenia—Carmustine—melanoma	4.53e-05	0.00126	CcSEcCtD
Vandetanib—Asthenia—Temozolomide—melanoma	4.38e-05	0.00122	CcSEcCtD
Vandetanib—Loss of consciousness—Docetaxel—melanoma	4.37e-05	0.00122	CcSEcCtD
Vandetanib—Cough—Docetaxel—melanoma	4.34e-05	0.00121	CcSEcCtD
Vandetanib—Diarrhoea—Carmustine—melanoma	4.32e-05	0.0012	CcSEcCtD
Vandetanib—Pruritus—Temozolomide—melanoma	4.32e-05	0.0012	CcSEcCtD
Vandetanib—Convulsion—Docetaxel—melanoma	4.31e-05	0.0012	CcSEcCtD
Vandetanib—Nausea—Bleomycin—melanoma	4.3e-05	0.0012	CcSEcCtD
Vandetanib—Hypertension—Docetaxel—melanoma	4.3e-05	0.0012	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—melanoma	4.29e-05	0.0012	CcSEcCtD
Vandetanib—ABCC1—lymph node—melanoma	4.26e-05	0.00135	CbGeAlD
Vandetanib—Rash—Dactinomycin—melanoma	4.26e-05	0.00119	CcSEcCtD
Vandetanib—Chest pain—Docetaxel—melanoma	4.24e-05	0.00118	CcSEcCtD
Vandetanib—Arthralgia—Docetaxel—melanoma	4.24e-05	0.00118	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	4.21e-05	0.00117	CcSEcCtD
Vandetanib—Dizziness—Carmustine—melanoma	4.18e-05	0.00116	CcSEcCtD
Vandetanib—Diarrhoea—Temozolomide—melanoma	4.18e-05	0.00116	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—melanoma	4.14e-05	0.00115	CcSEcCtD
Vandetanib—Oedema—Docetaxel—melanoma	4.06e-05	0.00113	CcSEcCtD
Vandetanib—Dizziness—Temozolomide—melanoma	4.04e-05	0.00112	CcSEcCtD
Vandetanib—Infection—Docetaxel—melanoma	4.04e-05	0.00112	CcSEcCtD
Vandetanib—Vomiting—Carmustine—melanoma	4.02e-05	0.00112	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—melanoma	4.01e-05	0.00112	CcSEcCtD
Vandetanib—Rash—Carmustine—melanoma	3.98e-05	0.00111	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—melanoma	3.98e-05	0.00111	CcSEcCtD
Vandetanib—Dermatitis—Carmustine—melanoma	3.98e-05	0.00111	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—melanoma	3.98e-05	0.00111	CcSEcCtD
Vandetanib—Headache—Carmustine—melanoma	3.96e-05	0.0011	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—melanoma	3.95e-05	0.0011	CcSEcCtD
Vandetanib—Vomiting—Temozolomide—melanoma	3.88e-05	0.00108	CcSEcCtD
Vandetanib—Rash—Temozolomide—melanoma	3.85e-05	0.00107	CcSEcCtD
Vandetanib—Dermatitis—Temozolomide—melanoma	3.85e-05	0.00107	CcSEcCtD
Vandetanib—Headache—Temozolomide—melanoma	3.83e-05	0.00107	CcSEcCtD
Vandetanib—Nausea—Carmustine—melanoma	3.75e-05	0.00105	CcSEcCtD
Vandetanib—Afatinib—ABCB1—melanoma	3.74e-05	0.0125	CrCbGaD
Vandetanib—Musculoskeletal discomfort—Docetaxel—melanoma	3.7e-05	0.00103	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—melanoma	3.67e-05	0.00102	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—melanoma	3.65e-05	0.00102	CcSEcCtD
Vandetanib—Nausea—Temozolomide—melanoma	3.63e-05	0.00101	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—melanoma	3.62e-05	0.00101	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—melanoma	3.58e-05	0.000996	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—melanoma	3.53e-05	0.000983	CcSEcCtD
Vandetanib—ABCG2—lymph node—melanoma	3.53e-05	0.00112	CbGeAlD
Vandetanib—Gastrointestinal disorder—Docetaxel—melanoma	3.51e-05	0.000976	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—melanoma	3.5e-05	0.000975	CcSEcCtD
Vandetanib—Pain—Docetaxel—melanoma	3.47e-05	0.000967	CcSEcCtD
Vandetanib—Constipation—Docetaxel—melanoma	3.47e-05	0.000967	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—melanoma	3.32e-05	0.000925	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—melanoma	3.21e-05	0.000894	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—melanoma	3.21e-05	0.000894	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—melanoma	2.91e-05	0.000811	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—melanoma	2.87e-05	0.0008	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—melanoma	2.78e-05	0.000774	CcSEcCtD
Vandetanib—Erlotinib—ALB—melanoma	2.77e-05	0.00928	CrCbGaD
Vandetanib—Dizziness—Docetaxel—melanoma	2.69e-05	0.000748	CcSEcCtD
Vandetanib—Erlotinib—ABCB1—melanoma	2.64e-05	0.00885	CrCbGaD
Vandetanib—Vomiting—Docetaxel—melanoma	2.58e-05	0.000719	CcSEcCtD
Vandetanib—Rash—Docetaxel—melanoma	2.56e-05	0.000713	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—melanoma	2.56e-05	0.000712	CcSEcCtD
Vandetanib—Headache—Docetaxel—melanoma	2.54e-05	0.000709	CcSEcCtD
Vandetanib—Nausea—Docetaxel—melanoma	2.41e-05	0.000672	CcSEcCtD
Vandetanib—Gefitinib—ALB—melanoma	1.73e-05	0.00581	CrCbGaD
Vandetanib—Gefitinib—ABCB1—melanoma	1.65e-05	0.00554	CrCbGaD
Vandetanib—Bosutinib—ABCB1—melanoma	1.63e-05	0.00546	CrCbGaD
Vandetanib—ABL1—Immune System—HRAS—melanoma	2.76e-07	3.17e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—melanoma	2.76e-07	3.17e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—melanoma	2.76e-07	3.17e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—melanoma	2.76e-07	3.16e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—melanoma	2.75e-07	3.16e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—melanoma	2.75e-07	3.16e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—melanoma	2.75e-07	3.16e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—melanoma	2.75e-07	3.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—melanoma	2.74e-07	3.15e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—melanoma	2.74e-07	3.15e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKB1—melanoma	2.74e-07	3.14e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—melanoma	2.73e-07	3.14e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—melanoma	2.73e-07	3.13e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—melanoma	2.72e-07	3.13e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—melanoma	2.72e-07	3.12e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—melanoma	2.72e-07	3.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MAPK1—melanoma	2.72e-07	3.12e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—melanoma	2.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—melanoma	2.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—melanoma	2.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—melanoma	2.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—melanoma	2.71e-07	3.11e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKB1—melanoma	2.69e-07	3.09e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—melanoma	2.69e-07	3.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—melanoma	2.68e-07	3.08e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—melanoma	2.68e-07	3.07e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—melanoma	2.68e-07	3.07e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAP2K1—melanoma	2.67e-07	3.06e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—melanoma	2.66e-07	3.05e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—melanoma	2.65e-07	3.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—melanoma	2.65e-07	3.04e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—melanoma	2.65e-07	3.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—melanoma	2.64e-07	3.03e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—melanoma	2.64e-07	3.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP17A1—melanoma	2.63e-07	3.02e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—melanoma	2.62e-07	3.01e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—melanoma	2.62e-07	3e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK1—melanoma	2.62e-07	3e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—melanoma	2.62e-07	3e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—melanoma	2.62e-07	3e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—melanoma	2.61e-07	3e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—melanoma	2.61e-07	2.99e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—melanoma	2.61e-07	2.99e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—melanoma	2.6e-07	2.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—melanoma	2.6e-07	2.98e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—melanoma	2.59e-07	2.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—melanoma	2.58e-07	2.97e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—melanoma	2.57e-07	2.94e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.55e-07	2.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—melanoma	2.55e-07	2.93e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—melanoma	2.55e-07	2.92e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—melanoma	2.54e-07	2.92e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—melanoma	2.54e-07	2.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—melanoma	2.54e-07	2.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—melanoma	2.54e-07	2.91e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—melanoma	2.52e-07	2.9e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—melanoma	2.52e-07	2.89e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK1—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—melanoma	2.51e-07	2.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—melanoma	2.5e-07	2.87e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—melanoma	2.5e-07	2.87e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—melanoma	2.49e-07	2.86e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—melanoma	2.49e-07	2.86e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—melanoma	2.49e-07	2.85e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—melanoma	2.48e-07	2.85e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNA11—melanoma	2.48e-07	2.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—melanoma	2.47e-07	2.84e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—melanoma	2.47e-07	2.84e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—melanoma	2.46e-07	2.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—melanoma	2.46e-07	2.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—melanoma	2.45e-07	2.82e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—melanoma	2.45e-07	2.81e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—melanoma	2.45e-07	2.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—melanoma	2.45e-07	2.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—melanoma	2.45e-07	2.81e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—melanoma	2.44e-07	2.8e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—melanoma	2.44e-07	2.79e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—melanoma	2.43e-07	2.79e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FASN—melanoma	2.43e-07	2.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—melanoma	2.42e-07	2.78e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—melanoma	2.42e-07	2.78e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—melanoma	2.42e-07	2.78e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—melanoma	2.42e-07	2.77e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—melanoma	2.42e-07	2.77e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—melanoma	2.41e-07	2.77e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—melanoma	2.41e-07	2.76e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.4e-07	2.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—melanoma	2.4e-07	2.75e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—melanoma	2.4e-07	2.75e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—melanoma	2.4e-07	2.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—melanoma	2.39e-07	2.74e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—melanoma	2.39e-07	2.74e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—melanoma	2.37e-07	2.72e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—melanoma	2.37e-07	2.72e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—melanoma	2.37e-07	2.72e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—melanoma	2.36e-07	2.71e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—melanoma	2.36e-07	2.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—melanoma	2.35e-07	2.7e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—melanoma	2.35e-07	2.7e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—melanoma	2.35e-07	2.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—melanoma	2.34e-07	2.69e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—melanoma	2.34e-07	2.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—melanoma	2.34e-07	2.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—melanoma	2.34e-07	2.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—melanoma	2.33e-07	2.68e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKB1—melanoma	2.33e-07	2.67e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK1—melanoma	2.32e-07	2.66e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—melanoma	2.32e-07	2.66e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAQ—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD44—melanoma	2.31e-07	2.65e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—melanoma	2.3e-07	2.64e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—melanoma	2.29e-07	2.63e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—melanoma	2.29e-07	2.62e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK1—melanoma	2.28e-07	2.62e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—melanoma	2.28e-07	2.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—melanoma	2.28e-07	2.62e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—melanoma	2.28e-07	2.61e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—melanoma	2.27e-07	2.61e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—melanoma	2.27e-07	2.6e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—melanoma	2.26e-07	2.59e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—melanoma	2.26e-07	2.59e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—melanoma	2.25e-07	2.59e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—melanoma	2.25e-07	2.58e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKB1—melanoma	2.24e-07	2.57e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK1—melanoma	2.24e-07	2.57e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—melanoma	2.24e-07	2.57e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—melanoma	2.23e-07	2.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—melanoma	2.22e-07	2.55e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—melanoma	2.21e-07	2.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1B1—melanoma	2.21e-07	2.54e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK1—melanoma	2.2e-07	2.53e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—melanoma	2.2e-07	2.53e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—melanoma	2.2e-07	2.53e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—melanoma	2.19e-07	2.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—melanoma	2.18e-07	2.5e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—melanoma	2.18e-07	2.5e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—melanoma	2.18e-07	2.5e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—melanoma	2.17e-07	2.49e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—melanoma	2.16e-07	2.48e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—melanoma	2.14e-07	2.46e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—melanoma	2.13e-07	2.44e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—melanoma	2.12e-07	2.44e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—melanoma	2.12e-07	2.43e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—melanoma	2.11e-07	2.42e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—melanoma	2.11e-07	2.42e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—melanoma	2.1e-07	2.41e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—melanoma	2.09e-07	2.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—melanoma	2.09e-07	2.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—melanoma	2.09e-07	2.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—melanoma	2.09e-07	2.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—melanoma	2.09e-07	2.39e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—melanoma	2.08e-07	2.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—melanoma	2.07e-07	2.37e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—melanoma	2.05e-07	2.35e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—melanoma	2.04e-07	2.34e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—melanoma	2.04e-07	2.34e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—melanoma	2.02e-07	2.31e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—melanoma	2.01e-07	2.31e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—melanoma	2.01e-07	2.31e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—melanoma	2.01e-07	2.31e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—melanoma	2.01e-07	2.31e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—melanoma	2.01e-07	2.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—melanoma	2.01e-07	2.3e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—melanoma	2e-07	2.3e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—melanoma	2e-07	2.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—melanoma	2e-07	2.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKB1—melanoma	1.99e-07	2.28e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	1.98e-07	2.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—melanoma	1.94e-07	2.23e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—melanoma	1.94e-07	2.23e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—melanoma	1.93e-07	2.21e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—melanoma	1.93e-07	2.21e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—melanoma	1.93e-07	2.21e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—melanoma	1.92e-07	2.2e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—melanoma	1.91e-07	2.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK1—melanoma	1.9e-07	2.18e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—melanoma	1.88e-07	2.15e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—melanoma	1.87e-07	2.15e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—melanoma	1.87e-07	2.14e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—melanoma	1.86e-07	2.13e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—melanoma	1.86e-07	2.13e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—melanoma	1.85e-07	2.12e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—melanoma	1.85e-07	2.12e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—melanoma	1.84e-07	2.11e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—melanoma	1.83e-07	2.1e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK1—melanoma	1.83e-07	2.1e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—melanoma	1.83e-07	2.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—melanoma	1.82e-07	2.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—melanoma	1.8e-07	2.07e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—melanoma	1.8e-07	2.06e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—melanoma	1.8e-07	2.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—melanoma	1.78e-07	2.05e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—melanoma	1.78e-07	2.04e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—melanoma	1.78e-07	2.04e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—melanoma	1.78e-07	2.04e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—melanoma	1.77e-07	2.03e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—melanoma	1.75e-07	2.01e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—melanoma	1.73e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—melanoma	1.72e-07	1.97e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—melanoma	1.71e-07	1.96e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—melanoma	1.71e-07	1.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—melanoma	1.69e-07	1.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PRKCA—melanoma	1.68e-07	1.92e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—melanoma	1.66e-07	1.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—melanoma	1.66e-07	1.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—melanoma	1.65e-07	1.89e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—melanoma	1.64e-07	1.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK1—melanoma	1.62e-07	1.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—melanoma	1.62e-07	1.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.62e-07	1.86e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—melanoma	1.61e-07	1.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—melanoma	1.6e-07	1.83e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—melanoma	1.59e-07	1.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—melanoma	1.59e-07	1.82e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—melanoma	1.56e-07	1.79e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—melanoma	1.54e-07	1.77e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—melanoma	1.53e-07	1.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—melanoma	1.53e-07	1.75e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—melanoma	1.51e-07	1.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—melanoma	1.47e-07	1.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—melanoma	1.46e-07	1.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—melanoma	1.41e-07	1.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—melanoma	1.41e-07	1.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—melanoma	1.36e-07	1.56e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—melanoma	1.35e-07	1.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—melanoma	1.31e-07	1.51e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—melanoma	1.3e-07	1.49e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—melanoma	1.3e-07	1.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—melanoma	1.27e-07	1.46e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—melanoma	1.25e-07	1.43e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—melanoma	1.16e-07	1.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—melanoma	1.15e-07	1.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—melanoma	1.14e-07	1.31e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—melanoma	1.14e-07	1.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—melanoma	1.01e-07	1.16e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—melanoma	9.98e-08	1.14e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—melanoma	9.29e-08	1.07e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—melanoma	8.7e-08	9.98e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—melanoma	6.14e-08	7.04e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—melanoma	5.01e-08	5.75e-07	CbGpPWpGaD
